1.745

2.94% 0.045

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $1.745, with a volume of 185.05K. It is up +2.94% in the last 24 hours and down -9.33% over the past month. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Previous Close:

$1.70

Open:

$1.7

24h Volume:

185.05K

Relative Volume:

0.43

Market Cap:

$240.78M

Revenue:

Net Income/Loss:

$-45.44M

P/E Ratio:

-4.7162

EPS:

-0.37

Net Cash Flow:

$-42.28M

1W Performance:

+2.94%

1M Performance:

-9.33%

6M Performance:

+2.94%

1Y Performance:

-5.91%

1-Day Range:

$1.68

$1.795

1-Week Range:

$1.58

$1.83

52-Week Range:

$0.765

$2.34

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CMPX's Discussions on Twitter

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Nov 04, 2024

Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024 - MD Magazine

Oct 27, 2024

Oct 17, 2024

Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat

Oct 17, 2024

Oct 16, 2024

Treatment Resistant Depression Clinical Trials 2024: FDA - openPR

Oct 16, 2024

Oct 15, 2024

Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 15, 2024

Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News

Oct 15, 2024

Financial Snapshot: Analyzing Compass Therapeutics Inc (CMPX)’s Key Ratio Metrics - The Dwinnex

Oct 15, 2024

Oct 14, 2024

CMPX’s 2023 Market Dance: Up 26.92% – Time to Invest? - The InvestChronicle

Oct 14, 2024

Renaissance Technologies LLC Decreases Position in Imperial Petroleum Inc. (NASDAQ:IMPP) - Defense World

Oct 14, 2024

JetBlue Airways (NASDAQ:JBLU) Raised to “Sell” at StockNews.com - Defense World

Oct 14, 2024

Oct 08, 2024

Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA - openPR

Oct 08, 2024

Silicon Laboratories Inc. (NASDAQ:SLAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Oct 08, 2024

Oct 04, 2024

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com

Oct 04, 2024

Compass Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire

Oct 04, 2024

Oct 03, 2024